Dual Mechanisms of Apigenin and Luteolin Against Dengue Virus Serotype 2: Allosteric Inhibition of NS2B/NS3 Protease and Interference with Host C-Type Lectin Receptor-Mediated Entry
Abstract
Objective: This study aimed to perform a computational analysis of apigenin and luteolin, focusing on their biological activities, pharmacokinetic properties, and interactions with dengue virus serotype 2 (DENV-2) proteins and host cell receptors associated with viral entry.
Material and Methods: The biological activities of the compounds were first predicted using PASS Online to evaluate their potential pharmacological profiles. Pharmacokinetic properties, including gastrointestinal absorption, skin permeation, blood–brain barrier penetration, cytochrome P450 interactions, bioavailability score, and overall drug-likeness, were assessed using SwissADME. In addition, toxicity parameters, such as LD₅₀ values and organ-specific toxicities, were predicted using ProTox 3.0. Subsequently, molecular docking simulations were performed using the SeamDock web server to evaluate the binding affinities of the compounds with dengue viral proteins and host receptor targets.
Results: Both compounds exhibited favorable pharmacokinetic characteristics and low predicted toxicity, alongside antioxidant and anti-inflammatory activities. Docking simulations revealed that luteolin had a slightly stronger affinity (−7.74 kcal/mol) than apigenin (−7.67 kcal/mol) toward the NS2B-NS3 protease, particularly at allosteric sites.
In addition, both flavonoids displayed interactions with host C-type lectin receptors, suggesting potential interference with viral attachment and entry mechanisms.
Conclusion: These computational findings highlight apigenin and luteolin as promising anti-dengue candidates with dual mechanisms of action through viral protease inhibition and host receptor interactions, supported by favorable pharmacokinetic and safety profiles.
Keywords
Full Text:
PDFReferences
Dengue and severe dengue [homepage on the Internet]. Geneva: World Health Organization; 2024 [cited 2025 May 4]. Available from: https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue
Tsheten T, Gray DJ, Clements ACA, Wangdi K. Epidemiology and challenges of dengue surveillance in the WHO South-East Asia Region. Trans R Soc Trop Med Hyg 2021;115:583-99.
Pourzangiabadi M, Najafi H, Fallah A, Goudarzi A, Pouladi I. Dengue virus: etiology, epidemiology, pathobiology, and developments in diagnosis and control – a comprehensive review. Infect Genet Evol 2025;127:105710.
World Health Organization RO for SEA. WHO South-East Asia Region epidemiological bulletin: biweekly update, 10th edition (Reporting period: 05 May–18 May 2025) [Internet]. 2025 [cited 2025 Jun 26]. Available from: https://iris.who.int/bitstream/handle/10665/381499/9789290220831-eng.pdf?sequence=1
Yenamandra SP, Koo C, Chiang S, Lim HSJ, Yeo ZY, Ng LC, et al. Evolution, heterogeneity and global dispersal of cosmopolitan genotype of Dengue virus type 2. Sci Rep 2021;11:13496.
Sangkaew S, Ming D, Boonyasiri A, Honeyford K, Kalayanarooj S, Yacoub S, et al. Risk predictors of progression to severe disease during the febrile phase of dengue: a systematic review and meta-analysis. Lancet Infect Dis 2021;21:1014-26.
Phadungsombat J, Nakayama EE, Shioda T. Unraveling dengue virus diversity in Asia: an epidemiological study through genetic sequences and phylogenetic analysis. Viruses 2024;16:1046.
Soo KM, Khalid B, Ching SM, Chee HY. Meta-analysis of dengue severity during infection by different dengue virus serotypes in primary and secondary infections. PLoS One 2016;11:e0154760.
Kyle JL, Harris E. Global spread and persistence of dengue. Vol. 62, Annu Rev Microbiol 2008;62:71-92.
Lee MF, Long CM, Poh CL. Current status of the development of dengue vaccines. Vaccine X 2024;22:100604.
Flacco ME, Bianconi A, Cioni G, Fiore M, Calò GL, Imperiali G, et al. Systematic review immunogenicity, safety and efficacy of the dengue vaccine TAK-003: a meta-analysis. Vaccines (Basel) 2024;12:770.
Badshah SL, Faisal S, Muhammad A, Poulson BG, Emwas AH, Jaremko M. Antiviral activities of flavonoids. Biomed Pharmacother 2021;140:111596.
Shukla R, Pandey V, Vadnere GP, Lodhi S. Role of Flavonoids in Management of Inflammatory Disorders. In: Bioactive Food as Dietary Interventions for Arthritis and Related Inflammatory Diseases. 2nd ed. Elsevier; 2019:293–322.
Acchioni C, Acchioni M, Mancini F, Amendola A, Marsili G, Tirelli V, et al. A cellular screening platform, stably expressing DENV2 NS5, defines a novel anti-DENV mechanism of action of Apigenin based on STAT2 activation. Virology 2023;583:1-13.
Sarwar MW, Riaz A, Dilshad SMR, Al-Qahtani A, Nawaz-Ul-Rehman MS, Mubin M. Structure activity relationship (SAR) and quantitative structure activity relationship (QSAR) studies showed plant flavonoids as potential inhibitors of dengue NS2B-NS3 protease. BMC Struct Biol 2018;18:6.
Chandani SR, Thorat PA, Nanda RK, Chitlange SS. Docking of phytoconstituents of Cynodon dactylon on NS2B NS3 protease domain of dengue virus. Res J Pharm Technol 2019;12:5823–27.
Hengphasatporn K, Kaewmalai B, Jansongsaeng S, Badavath VN, Saelee T, Chokmahasarn T, et al. Alkyne-tagged apigenin, a chemical tool to navigate potential targets of flavonoid anti-dengue leads. Molecules 2021;26:6967.
Xia H, Xie X, Zou J, Noble CG, Russell WK, Holthauzen LMF, et al. A cocrystal structure of dengue capsid protein in complex of inhibitor. Proc Natl Acad Sci U S A 2020;117:17992-8001.
Modis Y, Ogata S, Clements D, Harrison SC. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A 2003;100:6986-91.
Renner M, Flanagan A, Dejnirattisai W, Puttikhunt C, Kasinrerk W, Supasa P, et al. Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus. Nat Immunol 2018;19:1248-1256.
Modhiran N, Song H, Liu L, Bletchly C, Brillault L, Amarilla AA, et al. A broadly protective antibody that targets the flavivirus NS1 protein. Science 2021;371:190-94.
Erbel P, Schiering N, D’Arcy A, Renatus M, Kroemer M, Lim SP, et al. Structural basis for the activation of flaviviral NS3 proteases from dengue and west nile virus. Nat Struct Mol Biol 2006;13:372-3.
Xu T, Sampath A, Chao A, Wen D, Nanao M, Chene P, et al. Structure of the dengue virus helicase/nucleoside triphosphatase catalytic domain at a resolution of 2.4 Å. J Virol 2005;79:10278-88.
Egloff MP, Decroly E, Malet H, Selisko B, Benarroch D, Ferron F, et al. Structural and functional analysis of methylation and 5′-RNA sequence requirements of short capped RNAs by the methyltransferase domain of dengue virus NS5. J Mol Biol 2007;372:723-36.
Lim SP, Noble CG, Seh CC, Soh TS, El Sahili A, Chan GKY, et al. Potent allosteric dengue virus NS5 polymerase inhibitors: mechanism of action and resistance profiling. PLoS Pathog 2016;12:e1005737.
Guo Y, Feinberg H, Conroy E, Mitchell DA, Alvarez R, Blixt O, et al. Structural basis for distinct ligand-binding and targeting properties of the receptors DC-SIGN and DC-SIGNR. Nat Struct Mol Biol 2004;11:591-8.
Watson AA, Lebedev AA, Hall BA, Fenton-May RI, Vagin AA, Dejnirattisai W, et al. Structural flexibility of the macrophage dengue virus receptor CLEC5A: implications for ligand binding and signaling. J Biol Chem 2011;286:24208-18.
López-Blanco JR, Aliaga JI, Quintana-Ortí ES, Chacón P. IMODS: internal coordinates normal mode analysis server. Nucleic Acids Res 2014;42:W271-6.
Panda S, Kar A. Apigenin (4‘,5,7-trihydroxyflavone) regulates hyperglycaemia, thyroid dysfunction and lipid peroxidation in alloxan-induced diabetic mice. J Pharm Pharmacol 2007;59:1543-8.
Liu CW, Lin HW, Yang DJ, Chen SY, Tseng JK, Chang TJ, et al. Luteolin inhibits viral-induced inflammatory response in RAW264.7 cells via suppression of STAT1/3 dependent NF-KB and activation of HO-1. Free Radic Biol Med 2016;95:180-9.
Salehi B, Venditti A, Sharifi-Rad M, Kręgiel D, Sharifi-Rad J, Durazzo A, et al. The therapeutic potential of Apigenin. Int J Mol Sci 2019;20:1305.
Kimura Y, Ito H, Ohnishi R, Hatano T. Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity. Food Chem Toxicol 2010;48:429-35.
Daina A, Michielin O, Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017;7:42717.
Miron A, Aprotosoaie AC, Trifan A, Xiao J. Flavonoids as modulators of metabolic enzymes and drug transporters. Ann N Y Acad Sci 2017;1398:152–67.
Banerjee P, Kemmler E, Dunkel M, Preissner R. ProTox 3.0: A webserver for the prediction of toxicity of chemicals. Nucleic Acids Res 2024;52:W513–20..
Zandi K, Teoh BT, Sam SS, Wong PF, Mustafa M, Abubakar S. Antiviral activity of four types of bioflavonoid against dengue virus type-2. Virol J 2011;8:560.
Mukhtar M, Khan HA, Zaidi N us SS. Exploring the inhibitory potential of Nigella sativa against dengue virus NS2B/NS3 protease and NS5 polymerase using computational approaches. RSC Adv 2023;13:18306-322.
Peng M, Watanabe S, Chan KWK, He Q, Zhao Y, Zhang Z, et al. Luteolin restricts dengue virus replication through inhibition of the proprotein convertase furin. Antiviral Res 2017;143:176-85.
Chambers TJ, Hahn CS, Galler R, Rice CM. Flavivirus genome organization, expression, and replication. Annu Rev Microbiol 1990;44:649-88. doi: 10.1146/annurev.mi.44.100190.003245.
Wahaab A, Mustafa BE, Hameed M, Stevenson NJ, Anwar MN, Liu K, et al. Potential role of flavivirus NS2B-NS3 proteases in viral pathogenesis and anti-flavivirus drug discovery employing animal cells and models: a review. Viruses 2021;14:44.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.